Boniva (ibandronate sodium) Injection

Published Online: Wednesday, March 1, 2006

Roche (Nutley, NJ) and Glaxo-SmithKline (Research Triangle Park, NC) recently received FDA approval for Boniva Injection—the first intravenous (IV) medication indicated for the treatment of postmenopausal osteoporosis. The product is a member of the bisphosphonate class, which is the most frequently prescribed medicine for osteoporosis. Boniva Injection, administered as a 15-to 30-second IV injection, will provide an alternative for patients who have difficulty with oral bisphosphonate dosing requirements. Furthermore, because the product will be administered once every 3 months by health care professionals, clinicians will have a greater awareness of patient compliance with therapy. Boniva Injection 3 mg/3 mL will be available in boxes containing one single- use, clear glass prefilled syringe, along with 1 needle and an alcohol swab. For more information, visit www.gsk.com or www.rocheusa.com.




Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues
$auto_registration$
VSEO N/A